Leprosy is a chronic infection caused by the bacteria Mycobacterium leprae or Mycobacterium lepromatosis causing granulomas of the nerves, respiratory tract etc. The granulomas may result in lack of ability to feel pain, especially in the extremities such as finger tips. The global market for leprosy is falling due to early detection and awareness campaigns and integration of basic leprosy services into general health services of many countries.
Considering all these factors the market for leprosy treatment is expected to reach $ 3.5 billion by the end of 2023, this market is projected to growing at a CAGR of ~ 3.2 % during 2017-2023.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/3862
The global leprosy treatment market is segmented on the basis of drug class, disease type and market channel. Based on drug class, the market has been segmented as sulfone, phenazine, derivative, anti-tubercular drugs and others. Based on the disease type, the market has been segmented as paucibacillary leprosy, multibacillary leprosy. Based on the end users, the market has been segmented as private, contract and others.
US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. The faster market uptake of new technology in the US is also an important driver of the market for global leprosy treatment. Europe is the second largest market due to large disposable income and rising awareness. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa are expected to be a laggard due to poor economic and political conditions and poor healthcare penetration.Asia Pacific region is expected to have the most potential and it is estimated to be led by China and India.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/leprosy-treatment-market-3862